Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...

Advanced imaging technologies are uncovering surprising roles for CD8+ T cells—not just in immune defense, but also in supporting tissue repair and regeneration.

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results ...

Forte Biosciences (FBRX) announced data from a Phase 1b trial in celiac disease for lead program FB102. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized. Subjects ...

The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge.

Forte Biosciences (FBRX) stock soared on Monday after the clinical-stage biopharmaceutical company announced results from a Phase 1b trial of FB102. This is the company’s lead program designed to ...

Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.

APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and neck cancers, where Nectin-4 is highly expressed.